Scholarlink

<p>Pancreatic cancer, one of the most challenging malignancies to treat, is characterized by poor survival rates. The identification of novel effective therapies, optimization of treatments for the elderly population, and elucidation of the role of chemoradiotherapy are critical issues. Recent studies presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting have demonstrated advancements in the treatment of this aggressive disease. This review summarizes three notable studies: the phase&#xa0;I trial of IBI389, the phase&#xa0;II GIANT trial, and the phase&#xa0;II/III GABARNANCE trial, each contributing new insights into therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in pancreatic cancer treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月9日

查看全文
  • Hossein Taghizadeh

摘要

Pancreatic cancer, one of the most challenging malignancies to treat, is characterized by poor survival rates. The identification of novel effective therapies, optimization of treatments for the elderly population, and elucidation of the role of chemoradiotherapy are critical issues. Recent studies presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting have demonstrated advancements in the treatment of this aggressive disease. This review summarizes three notable studies: the phase I trial of IBI389, the phase II GIANT trial, and the phase II/III GABARNANCE trial, each contributing new insights into therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC).